The resurrection of Gnbt has been great, but what we’ve been hearing about NuGenerex and financing etc has been ongoing since 2017. I, like all, appreciate how hard it must be. But, we aren’t a fan club. We are investors. We empathize. We support, as we have to Joe since he told us he basically runs Gnbt since 2010. Patience isn’t something we lack. It’s always expected in such a company. But I see fast declining revenue in two, venteto and fuse, major companies we are acquiring, as they value them on the higher end of the revenue. It’s not on us to accept this, but on them to explain. It’s not being negative to honestly ask -why? Why is Gnbt valuing so high? It should be a concern. And if it’s not, then it should be easily discussed on the CC.
(3)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links